| dbo:abstract
|
- GS-6620 is an antiviral drug which is a nucleotide analogue. It was developed for the treatment of Hepatitis C but while it showed potent antiviral effects in early testing, it could not be successfully formulated into an oral dosage form due to low and variable absorption in the intestines which made blood levels unpredictable. It has however continued to be researched as a potential treatment for other viral diseases such as Ebola virus disease. (en)
- GS-6620是一种核苷酸类的抗病毒药物，被开发用于治疗丙型肝炎。尽管它在早期测试中显示出有效的抗病毒作用，但由于它在肠道中的吸收率低且效果不稳定（无法预测血液中的浓度），未能成功制成口服剂。目前进行的研究主要针对其它疾病（如埃博拉出血热）的治疗。 (zh)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:fdaUniiCode
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 4369 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:dtxsid
| |
| dbp:h
| |
| dbp:iupacName
|
- [-5--5-cyano-4-hydroxy-4-methyl-2-[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate (en)
|
| dbp:legalUs
|
- Investigational New Drug (en)
|
| dbp:molecularWeight
| |
| dbp:n
| |
| dbp:o
| |
| dbp:p
| |
| dbp:pubchem
| |
| dbp:smiles
|
- C[C@@H]NPOC4=CC=CC=C4 (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- YAAQYJCOIFNMKX-CVANIGNKSA-N (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- GS-6620 is an antiviral drug which is a nucleotide analogue. It was developed for the treatment of Hepatitis C but while it showed potent antiviral effects in early testing, it could not be successfully formulated into an oral dosage form due to low and variable absorption in the intestines which made blood levels unpredictable. It has however continued to be researched as a potential treatment for other viral diseases such as Ebola virus disease. (en)
- GS-6620是一种核苷酸类的抗病毒药物，被开发用于治疗丙型肝炎。尽管它在早期测试中显示出有效的抗病毒作用，但由于它在肠道中的吸收率低且效果不稳定（无法预测血液中的浓度），未能成功制成口服剂。目前进行的研究主要针对其它疾病（如埃博拉出血热）的治疗。 (zh)
|
| rdfs:label
|
- GS-6620 (en)
- GS-6620 (zh)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is foaf:primaryTopic
of | |
